Core Concepts
Not all patients with IPF should be on antifibrotic therapy; individualized treatment is key.
Abstract
Introduction to IPF and antifibrotic therapy.
Dr. Adegunsoye's personal story and motivation to work with IPF patients.
Discussion on the decision-making process for antifibrotic therapy.
Comparing nintedanib and pirfenidone for IPF treatment.
Approach to managing patients who do not respond to initial antifibrotic therapy.
Insights on acute exacerbations in IPF and treatment strategies.
Key takeaways on IPF management and the importance of early intervention.
Hope for future advancements in IPF treatment.
Stats
"Every year, about 5%-15% of patients with IPF will develop this worsening of their baseline disease state."
"Patients who are on antifibrotic therapy — be it nintedanib or pirfenidone — are going to lose 100, 115, 120 cc's of FVC over 52 weeks."
"The short-term mortality is typically about 40%-50% for acute exacerbations in IPF."
Quotes
"Not all cough is COPD and not all shortness of breath is heart failure."
"Early intervention is key."
"Hope is on the horizon."